The Utrecht Center for Pharmaceutical Policy and Regulation connects high-quality academic research and methodological advances with innovative healthcare policies, particularly related to regulation and reimbursement of drugs. 

The focus of my research within this Center, (part of the Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Institute for Pharmaceutical Sciences) is the link between drug regulation and health economics. I investigate current policies and develop novel methodologies to facilitate the pathway from drug development to patient access. My focus lies on novel therapeutics, particularly those approved via facilitated regulatory pathways (e.g. conditional approvals or approvals under exceptional circumstances), orphan drugs, and advanced therapy medicinal products (gene and cell therapies). 

Specifically, I investigate how uncertainty is managed throughout the drug lifecycle by regulatory agencies and health technology assessment organizations. I developed new methods to categorize and quantify uncertainty and I have developed policy solutions for aligning regulatory and HTA activities. Additionally, my work focuses on improving pharmaceutical policy analyses through collaboration with data science groups for the development of innovative data extraction and analysis techniques. 

I combine my work at Utrecht University with a part-time appointment at the National Health Care Institute (Zorginstituut Nederland, ZIN) where I advise on improving the methodologies ZIN uses to evaluate technologies for their inclusion in the universal healthcare package in the Netherlands.